Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific

Derek L. Stirewalt, Cheryl L. Willman, Jerald P. Radich

Research output: Contribution to journalArticlepeer-review

Abstract

Internal tandem duplications (ITDs) of the FLT3 gene occur in ≈K20-30% of acute myeloid leukemia (AML) patients. We investigated if FLT3 ITDs could be used as minimal residual disease (MRD) markers for AML patients. Patient-specific polymerase chain reaction (PCR) assays for FLT3 ITDs were developed for four AML samples that contained FLT3 ITDs of varying size and location. The real-time, quantitative PCR assays for FLT3 ITDs were highly sensitive and specific, detecting between 0.01 and 0.001% of FLT3 ITD positive DNA in a background of 1 μg of normal bone marrow DNA. Our findings suggest that FLT3 ITDs can be used as molecular markers for MRD in patients with AML.

Original languageEnglish (US)
Pages (from-to)1085-1088
Number of pages4
JournalLeukemia Research
Volume25
Issue number12
DOIs
StatePublished - 2001

Keywords

  • FLT3
  • Leukemia
  • Minimal residual disease
  • Myeloid

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific'. Together they form a unique fingerprint.

Cite this